Amyloid inhibition by molecular chaperones <i>in vitro</i> can be translated to Alzheimer's pathology <i>in vivo</i>
Axel Abelein, Jan Johansson
Abstract
. Interestingly, recent immunotherapy advances, which have demonstrated significant improvements in clinical phase III trials, have used antibodies that selectively act against Aβ oligomer formation, supporting the notion that specific inhibition of Aβ neurotoxicity is more rewarding than reducing overall amyloid fibril formation. Hence, specific modulation of chaperone activity represents a promising new strategy for treatment of neurodegenerative disorders.
Topics & Concepts
In vivoIn vitroNeurotoxicityAmyloid (mycology)OligomerProtein aggregationAlzheimer's diseaseChemistryChaperone (clinical)Cell biologyNeuroscienceBiologyDiseaseMedicineBiochemistryPathologyToxicityOrganic chemistryBiotechnologyInorganic chemistryEndoplasmic Reticulum Stress and DiseaseAlzheimer's disease research and treatmentsHeat shock proteins research